论文部分内容阅读
目的分析急性期脑梗死患者行依达拉奉药物治疗的效果。方法选取该院神经内科2012年6月—2014年12月收治的120例急性期脑梗死患者作为临床研究对象,采用随机数字法将120例患者均分为观察组与对照组,二组患者均给予常规基础治疗,对照组于常规治疗基础上加用胞二磷胆碱药物治疗方案,观察组于常规基础治疗之上联合依达拉奉静脉滴注治疗,对比二组患者临床疗效。结果观察组患者治疗总有效率显著高于对照组(P<0.05);治疗前后二组患者神经功能缺损(NIHSS)评分、日常生活活动能力(ADL)量表评分均得到了显著改善,观察组改善情况显著优于对照组(P<0.05);二组患者治疗期间均未见明显不良反应。结论急性脑梗死患者临床应用依达拉奉药物治疗,可显著改善患者神经功能、生活能力,临床综合疗效显著,值得进一步应用推广。
Objective To analyze the effect of edaravone in patients with acute cerebral infarction. Methods A total of 120 patients with acute cerebral infarction who were admitted to our hospital from June 2012 to December 2014 were selected as the clinical study subjects. All 120 patients were divided into observation group and control group by random number method. The patients in the control group were treated with citicoline on the basis of routine treatment. The patients in the observation group were treated with edaravone intravenously on the basis of routine basic treatment, and the clinical efficacy was compared between the two groups. Results The total effective rate of observation group was significantly higher than that of control group (P <0.05). NIHSS score and ADL scale scores of two groups were significantly improved before and after treatment. The observation group Improvement was significantly better than the control group (P <0.05); two groups of patients during the treatment showed no significant adverse reactions. Conclusion The clinical application of edaravone in patients with acute cerebral infarction can significantly improve the neurological function and the living ability of the patients. The comprehensive clinical curative effect is significant and worthy of further application and popularization.